Table 1.
Characteristics of included studies and patient population.
| Author | Country | Design | No. of cancer patients | No. of controls | Patients' age (years) | Type of cancer | Vaccine type | Vaccine scheme | Reported outcomes |
|---|---|---|---|---|---|---|---|---|---|
| Addeo et al. [17] | Switzerland/USA | Multicentre, prospective, cohort | 244 | NA | 63 (IQR 55–69) | Haematological malignancy and solid tumour | mRNA (BNT162b2/mRNA1273) | Incomplete and complete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Agha et al. [41] | USA | Single-centre, prospective, cohort | 67 | NA | 71 (IQR 65–77) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Complete | Anti-S IgG Ab |
| Barrière et al. [42] | France | Single-centre, prospective, cohort | 122 | 29 | 69.5 (range 44–90) | Solid tumour | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, adverse effects |
| Benda et al. [37] | Austria | Single-centre, prospective, cohort | 259 | NA | 65.1 (SD 12.2) | Haematological malignancy and solid tumour | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Benjamini et al. [53] | Israel | Multicentre, prospective, cohort | 373 | NA | 70 (range 40–89) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, anti-N IgG Ab, adverse effects |
| Bird et al. [43] | UK | Single-centre, retrospective, cohort | 93 | NA | 67 (IQR 59–73) | Haematological malignancy | mRNA (BNT162b2) and viral vector (AZD1222) | Incomplete | Anti-S IgG Ab |
| Chowdhury et al. [44] | UK | Multi-centre, prospective, cohort | 59 | 232 | 62 (IQR 52–73) | Haematological malignancy | mRNA (BNT162b2) and viral vector (AZD1222) | Incomplete | Anti-S IgG Ab, anti-N IgG Ab |
| Cohen et al. [45] | Israel | Single-centre, prospective, cohort | 54 | NA | 68.8 (IQR 61.2–76.8) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, adverse effects |
| Ehmsen et al. [54] | Denmark | Single-centre, prospective | 524 | NA | 70 (IQR 63–75) | Haematological malignancy and solid tumour | mRNA | Complete | Anti-S IgG Ab, T-cell response |
| Ghandili et al. [47] | Germany | Single-centre, prospective, cohort | 74 | NA | 67.5 (range 40–85) | Haematological malignancy | mRNA and viral vector | Incomplete | Anti-S IgG Ab, SARS-CoV-2 infection |
| Ghione et al. [46] | USA | Multicentre, prospective, cohort | 86 | 201 | NA | Haematological malignancy | mRNA (BNT162b2/mRNA1273) and viral vector (AD26.COV2.S) | Complete | Anti-S IgG Ab |
| Goshen-Lago et al. [24] | Israel | Single-centre, prospective, cohort | 86 | 261 | 66 (SD 12.09) | Solid tumour | mRNA (BNT162b2) | Incomplete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Greenberger et al. [36] | USA | Prospective, cohort | 1445 | NA | 68 (range 16–110) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Complete | Anti-S IgG Ab |
| Guglielmelli et al. [51] | Italy | Single-centre, retrospective, cohort | 30 | 14 | 60.8 (range 36.9–80.3) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Incomplete | Anti-S IgG Ab |
| Harrington, Lavallade et al. [25] | UK | Single-centre, prospective, cohort | 21 | NA | 55 (SD 10.71) | Haematological malignancy | mRNA (BNT162b2) | Incomplete | Anti-S IgG Ab, anti-N IgG Ab, NAb, T-cell response, adverse effects |
| Harrington, Doores et al. [26] | UK | Multicentre, prospective, cohort | 16 | NA | 45.6 (SD 14.8) | Haematological malignancy | mRNA (BNT162b2) | Incomplete | Anti-S IgG Ab, anti-N IgG Ab, NAb, T-cell response, adverse effects |
| Herishanuet al [19] | Israel | Multicentre, prospective, cohort | 167 | 52 | 71 (IQR 63–76) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, anti-N IgG Ab, adverse effects |
| Heudel et al. [52] | France | Prospective, cohort | 1503 | NA | NA | Haematological malignancy and solid tumour | mRNA (BNT162b2/mRNA1273) and viral vector (ChAdOx1) | Incomplete and complete | Anti-S IgG Ab, SARS-CoV-2 infection |
| Karacin et al. [35] | Turkey | Multicentre, prospective, cohort | 47 | NA | 73 (range 64–80) | Solid tumour | Inactivated (CoronaVac) | Complete | Anti-S IgG Ab |
| Lim et al. [27] | UK | Multicentre, prospective, cohort | 129 | 150 | 69 (IQR 57–74) | Haematological malignancy | mRNA (BNT162b2) and viral vector (ChAdOx1) | Incomplete and complete | Anti-S IgG Ab, anti-N IgG Ab |
| Malard et al. [40] | France | Single-centre, retrospective, cohort | 195 | 30 | 68.8 (range 21.5–91.7) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, T-cell response |
| Maneikis et al. [28] | Lithuania | Single-centre, prospective, cohort | 857 | 68 | 65 (IQR 54–72) | Haematological malignancy | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Massarweh et al. [18] | Israel | Single-centre, prospective, cohort | 102 | 78 | 66 (IQR 56–72) | Solid tumour | mRNA (BNT162b2) | Complete | Anti-S IgG Ab |
| Monin et al. [20] | UK | Multicentre, prospective, cohort | 151 | 54 | 73 (IQR 64.5–79.5) | Haematological malignancy and solid tumour | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, T-cell response, adverse effects, SARS-CoV-2 infection |
| Palich et al. [29] | France | Single-centre, prospective, cohort | 110 | 25 | 66 (IQR 54–74) | Solid tumour | mRNA (BNT162b2) | Incomplete | Anti-S IgG Ab, anti-N IgG Ab |
| Parry et al. [48] | UK | Single-centre, prospective, cohort | 286 | 93 | 69 (IQR 63–74) | Haematological malignancy | mRNA (BNT162b2) and viral vector (ChAdOx1) | Incomplete and complete | Anti-S IgG Ab |
| Pimpinelli et al. [30] | Italy | Single-centre, prospective, cohort | 92 | 36 | 74 (range 47–78) | Haematological malignancy | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Pimpinelli, Marchesi et al. [50] | Italy | Single-centre, prospective | 42 | NA | 72 (range 52–82) | Haematological malignancy | mRNA (BNT162b2) | Incomplete | Anti-S IgG Ab |
| Re et al. [39] | France | Prospective, cohort | 45 | NA | 77 (range 37–92) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, anti-N IgG Ab, T-cell response |
| Revon-Riviere et al. [31] | France | Single-centre, retrospective, cohort | 13 | NA | 17 (IQR 16–18) | Haematological malignancy and solid tumour | mRNA (BNT162b2) | Incomplete and complete | Anti-S IgG Ab, adverse effects, SARS-CoV-2 infection |
| Re, Barrière et al. [38] | France | Single-centre, retrospective, cohort | 102 | NA | 75.5 (range 33–93) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Complete | Anti-S IgG Ab |
| Stampfer et al. [49] | USA | Single-centre, prospective, cohort | 103 | 31 | 68 (range 35–88) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Incomplete and complete | Anti-S IgG Ab, SARS-CoV-2 infection |
| Thakkar et al. [32] | USA | Multicentre, retrospective, cohort | 200 | 26 | 67 (range 27–90) | Haematologic malignancy and solid tumour | mRNA (BNT162b2/mRNA1273) and viral vector (AD26.COV2.S) | Complete | Anti-S IgG Ab, adverse effects |
| Tzarfati et al. [33] | Israel | Single-centre, prospective, cohort | 315 | 108 | 71 (IQR 61–78) | Haematological malignancy | mRNA (BNT162b2) | Complete | Anti-S IgG Ab, SARS-CoV-2 infection |
| Van Oekelen et al. [34] | USA | Single-centre, retrospective, cohort | 320 | 67 | 68 (range 38–93) | Haematological malignancy | mRNA (BNT162b2/mRNA1273) | Complete | Anti-S IgG Ab, SARS-CoV-2 infection |
Data are expressed as no. (%) unless otherwise noted.
Abbreviations: USA, United States of America; UK, United Kingdom; NA, not available; IQR, interquartile range; SD, standard deviation; Anti-S Ab, anti-spike antibody; Anti-N Ab, anti-nucleocapsid antibody; NAb, neutralising antibody; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.